Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NATHALIE C ZEITOUNI

Allopathic & Osteopathic Physicians Dermatology

NPI
1164403010
CMS profile
143665
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$107,250.21

104 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NATHALIE C ZEITOUNI

NPI 1164403010 · CMS profile ID 143665

Allopathic & Osteopathic Physicians / Dermatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1164403010?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NATHALIE C ZEITOUNI, NPI 1164403010, CMS profile ID 143665. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1164403010?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). NATHALIE C ZEITOUNI, NPI 1164403010, CMS profile ID 143665. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1164403010?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
NATHALIE C ZEITOUNI, NPI 1164403010, CMS profile ID 143665, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 104 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1164403010?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

104 matching records · $107,250.21 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 104 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 104.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $18.9807/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842277885 CMS
Amgen Inc. $6.8907/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401189 CMS
Lilly USA, LLC $19.9507/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818659201 CMS
Amgen Inc. $8.9807/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401185 CMS
Regeneron Pharmaceuticals, Inc. $2,820.0007/09/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809682349 CMS
Biofrontera Inc. $60.3207/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803505469 CMS
Amgen Inc. $8.3606/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401181 CMS
Genentech USA, Inc. $1,750.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835956825 CMS
Regeneron Healthcare Solutions, Inc. $1,408.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638599 CMS
Genentech USA, Inc. $8,000.0006/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835956813 CMS
Genentech USA, Inc. $125.0006/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835956815 CMS
Genentech USA, Inc. $129.9806/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835956819 CMS
Genentech USA, Inc. $132.1606/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835956821 CMS
GENZYME CORPORATION $2,112.0006/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568963 CMS
Regeneron Healthcare Solutions, Inc. $27.5906/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638587 CMS
Regeneron Healthcare Solutions, Inc. $81.1006/03/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638589 CMS
Regeneron Healthcare Solutions, Inc. $8.9906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638591 CMS
Regeneron Healthcare Solutions, Inc. $8.1606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638593 CMS
Regeneron Healthcare Solutions, Inc. $4.1206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638595 CMS
Regeneron Healthcare Solutions, Inc. $6.7906/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638597 CMS
Amgen Inc. $6.4806/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401177 CMS
LEO Pharma Inc. $19.6805/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842277877 CMS
GENZYME CORPORATION $2,464.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568949 CMS
Regeneron Healthcare Solutions, Inc. $7,392.0005/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638585 CMS
Regeneron Healthcare Solutions, Inc. $150.1205/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638581 CMS
Regeneron Healthcare Solutions, Inc. $174.1205/16/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638583 CMS
Regeneron Healthcare Solutions, Inc. $128.0805/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638579 CMS
Regeneron Healthcare Solutions, Inc. $71.0905/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638577 CMS
Regeneron Healthcare Solutions, Inc. $306.4005/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638573 CMS
Regeneron Healthcare Solutions, Inc. $356.9805/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809638575 CMS
Amgen Inc. $23.9604/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401173 CMS
Almirall LLC $800.0004/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819687681 CMS
AbbVie Inc. $28.2904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796303483 CMS
GENZYME CORPORATION $2,464.0004/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568933 CMS
Almirall LLC $4,500.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819696405 CMS
GENZYME CORPORATION $5,280.0004/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568929 CMS
GENZYME CORPORATION $545.9304/08/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568931 CMS
GENZYME CORPORATION $121.8304/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843569079 CMS
GENZYME CORPORATION $2,464.0004/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568927 CMS
Amgen Inc. $8.0904/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401169 CMS
GENZYME CORPORATION $2,464.0004/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843568935 CMS
Bausch Health US, LLC $14.0003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851573667 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $5,000.0003/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851915273 CMS
Amgen Inc. $22.9003/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826401165 CMS
Incyte Corporation $51.2603/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835573615 CMS
Lilly USA, LLC $15.0903/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818656829 CMS
Almirall LLC $1,625.0002/28/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819699709 CMS
AbbVie Inc. $22.1202/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796303481 CMS
AbbVie Inc. $19.4702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796303479 CMS
GENZYME CORPORATION $1,056.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843569159 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $106,395.14 119
PY2020 $40,906.98 40
PY2021 $107,250.21 104
PY2022 $80,542.34 98
PY2023 $64,864.98 77
PY2024 $84,125.98 95
PY2025 $100,179.10 75

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,809.11 33
PY2025 Principal investigator $122,254.05 18
PY2024 Recipient $522.38 2
PY2024 Principal investigator $152,009.57 9
PY2023 Principal investigator $242,240.86 15
PY2022 Principal investigator $95,189.55 3
PY2021 Principal investigator $43,250.10 5
PY2020 Principal investigator $152,601.99 7
PY2019 Recipient $24,059.88 4
PY2019 Principal investigator $9,369.40 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,333.49 11/20/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184263373
Recipient Regeneron Pharmaceuticals, Inc. $37.29 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124174
Recipient Regeneron Pharmaceuticals, Inc. $243.73 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124176
Recipient Regeneron Pharmaceuticals, Inc. $223.50 11/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124178
Recipient Regeneron Pharmaceuticals, Inc. $53.87 10/23/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124170
Recipient Regeneron Pharmaceuticals, Inc. $293.78 10/23/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124172
Recipient Regeneron Pharmaceuticals, Inc. $53.87 09/16/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124168
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $0.23 09/12/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184236922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,476.60 08/14/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184228533
Recipient Regeneron Pharmaceuticals, Inc. $53.87 08/13/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124166
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,265.72 08/06/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184223628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,524.46 07/10/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184214596
Recipient Regeneron Pharmaceuticals, Inc. $13.34 06/26/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124162
Recipient Regeneron Pharmaceuticals, Inc. $70.43 06/26/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124164
Principal investigator 1 Biofrontera Inc. $7.67 06/25/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907480
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,507.74 06/19/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184209346
Recipient Regeneron Pharmaceuticals, Inc. $51.86 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124148
Recipient Regeneron Pharmaceuticals, Inc. $57.46 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124150
Recipient Regeneron Pharmaceuticals, Inc. $98.90 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124152
Recipient Regeneron Pharmaceuticals, Inc. $103.02 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124154
Recipient Regeneron Pharmaceuticals, Inc. $127.07 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124156
Recipient Regeneron Pharmaceuticals, Inc. $351.03 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124158
Recipient Regeneron Pharmaceuticals, Inc. $418.88 06/12/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124160
Recipient Regeneron Pharmaceuticals, Inc. $150.00 06/11/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124146
Recipient Regeneron Pharmaceuticals, Inc. $310.40 06/01/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124144
Recipient Regeneron Pharmaceuticals, Inc. $586.81 05/05/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124142
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,199.23 04/10/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184182878
Recipient Regeneron Pharmaceuticals, Inc. $310.40 04/03/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124140
Recipient Regeneron Pharmaceuticals, Inc. $53.87 03/25/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124138
Principal investigator 1 Biofrontera Inc. $27,483.50 03/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907379
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,362.36 03/13/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184173818
Recipient Regeneron Pharmaceuticals, Inc. $79.88 02/21/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124136
Principal investigator 1 Biofrontera Inc. $8.95 02/20/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907335
Recipient Regeneron Pharmaceuticals, Inc. $360.44 02/16/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124134
Recipient Regeneron Pharmaceuticals, Inc. $74.05 02/14/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124132
Principal investigator 1 Biofrontera Inc. $24.59 02/13/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,956.45 02/13/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184153976
Recipient Regeneron Pharmaceuticals, Inc. $162.74 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124120
Recipient Regeneron Pharmaceuticals, Inc. $223.00 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124122
Recipient Regeneron Pharmaceuticals, Inc. $68.89 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124124
Recipient Regeneron Pharmaceuticals, Inc. $30.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124126
Recipient Regeneron Pharmaceuticals, Inc. $96.17 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124128
Recipient Regeneron Pharmaceuticals, Inc. $62.01 02/07/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124130
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,576.00 02/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184152540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,118.00 02/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184152542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,502.00 02/05/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184152544
Recipient Regeneron Pharmaceuticals, Inc. $756.40 01/20/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124118
Recipient Regeneron Pharmaceuticals, Inc. $178.27 01/17/2025 Covered Recipient Physician A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC) No dispute reported 06/30/2026 1184124116
Principal investigator 1 Biofrontera Inc. $3,000.00 01/15/2025 Non-covered Recipient Entity
MEDICAL DERMATOLOGY SPECIALISTS
A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) No dispute reported 06/30/2026 1208907248
Recipient Regeneron Pharmaceuticals, Inc. $53.87 01/15/2025 Covered Recipient Physician LIBTAYO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1184124114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,907.06 01/03/2025 Non-covered Recipient Entity
SOUTHWEST SKIN SPECIALISTS LLC
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB (REGN2810), ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) OR BASAL CELL CARCINOMA (BCC) No dispute reported 06/30/2026 1184144838